Diclofenac Sodium/Misoprostol
Brand Names: Arthrotec
Methodology & AI Transparency ⓘ
Diclofenac Sodium/Misoprostol Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications.
- 2 Real-world patient consensus: Real-world cohort score of 83% across 20 de-identified Diclofenac Sodium/Misoprostol entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $16.82 wholesale mail-order against $41.21 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Diclofenac Sodium/Misoprostol tolerability events: nausea (11.7%), headache (10.3%), dizziness (6%).
Ask our AI Specialists anything about Diclofenac Sodium/Misoprostol
Diclofenac Sodium/Misoprostol Mechanism, CYP450 Pathways & DailyMed Monograph
Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. For a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications .
12.1 Mechanism of Action Diclofenac sodium and misoprostol delayed-release tablets are a combination product containing diclofenac sodium, an NSAID with analgesic, anti-inflammatory and antipyretic properties, and misoprostol, a GI mucosal protective prostaglandin-1 (PGE1) analog. Diclofenac The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin (PG) synthesis in vitro . Diclofenac concentrations reached during therapy have produced in vivo effects.
With Steady-state plasma equilibrium reached over 3–10 hour t½ intervals for Diclofenac Sodium/Misoprostol residence kinetics and Approximately 68% to 80% enteral uptake across labeled Diclofenac Sodium/Misoprostol strengths bioavailability, Diclofenac Sodium/Misoprostol undergoes predominantly hepatic biotransformation with renal elimination of polar diclofenac sodium/misoprostol conjugates and establishes therapeutic activity over maximum serum exposure occurs 2–4 hours after diclofenac sodium/misoprostol dosing.
Standard adult regimens span 75 mg/1 / 200 ug/1 Tablet, 50 mg/1 / 200 ug/1 Tablet, 50-0.2mg Tablet Delayed Release, 75-0.2mg Tablet Delayed Release. Prescribers screen specifically against diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients: pregnancy.; previous anaphylactoid or exfoliative reaction attributed to diclofenac sodium/misoprostol, while community micro-logs most frequently note nausea (11.7% of reports), headache (10.3% of reports), diarrhea (9% of reports).
Monitor kidney function and gastrointestinal symptoms when Diclofenac Sodium/Misoprostol overlaps with daily NSAID analgesia.
Verify medication reconciliation lists so Diclofenac Sodium/Misoprostol is not inadvertently duplicated with another prostaglandin e1 analog.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients: Pregnancy.
- Previous anaphylactoid or exfoliative reaction attributed to Diclofenac Sodium/Misoprostol
Logged Side-Effect Incidence (20 Reports)
Diclofenac Sodium/Misoprostol Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diclofenac Sodium/Misoprostol)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Real-world benefits and safety of NVP-1203 and aceclofenac in patients with acute: What a 455-Participant Study Found NVP-1203 is more effective in reducing pain than the 100 mg aceclofenac alone. European review for medical and pharmacological sciences • 2023-01-15 • Phase III Randomized Trial | N = 455 | 93/100 | PMID 36647880 ↗ |
| New Insights on Randomized, gold-standard blind, noninferiority study of diclofenac diethylamine: What a 302-Participant Study Found DDEA 2.32% gel BID offers a convenient alternative to DDEA 1.16% gel QID, with similar pain reduction and relief, anti-inflammatory effects, and tolerability. BMC musculoskeletal disorders • 2022-12-24 • Phase III Randomized Trial | N = 302 | 93/100 | PMID 36566202 ↗ |
| Targeted Pain Relief Without Stomach Upset: How Well Do Diclofenac Skin Patches Work? A short-course applied to the skin diclofenac epolamine patch, combined with rehabilitation training, effectively alleviates pain, accelerates functional recovery, and is safe for treating moderate hamstring strain, supporting... Pakistan journal of pharmaceutical sciences • 2027-01-01 • Randomized Controlled Trial | N = 120 | 88/100 | PMID 42924980 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Ushaq Capsule as add-on treatment in Patients With Lumbar Ushaq capsules as add-on treatment with diclofenac as rescue medication showed greater pain reduction compared to placebo with a favourable safety profile. Musculoskeletal care • 2026-12-15 • Randomized Controlled Trial | N = 68 | 88/100 | PMID 42935088 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Diclofenac-Hyaluronate Conjugate (Diclofenac Our findings indicate that treatment with DF-HA results in significant improvement in the WOMAC pain subscale score compared to placebo over 12 weeks. Arthritis & rheumatology (Hoboken, N.J.) • 2021-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33749997 ↗ |
Diclofenac Sodium/Misoprostol Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.6645/unit (~$19.93/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $16.82 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $41.21 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $19.34 / mo | View logs ↓ |
Diclofenac Sodium/Misoprostol Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Diclofenac Sodium/Misoprostol RxNorm Concept ID | 857706 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.6645 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $41.21 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $16.82 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 83.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Diclofenac Sodium/Misoprostol Patient Community, Cohort Filters & Dosage Logs
Cross-verified Diclofenac Sodium/Misoprostol (prostaglandin e1 analog) monograph synthesizing RxNorm 857706, openFDA FAERS signals, and $16.82–$41.21 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Diclofenac Sodium/Misoprostol community threads and patient logs by age, biological sex, dosage, and treatment duration.